Tempest Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 13, 2026, Tempest Therapeutics, Inc. announced and furnished a press release reporting its financial results for the quarter ended June 30, 2026 and other business highlights. The press release is attached to the Form 8-K as Exhibit 99.1. The report was signed by CEO Matthew Angel.

Key Details

• Form 8-K filed/furnished: August 13, 2026 (Item 2.02 - Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Attached exhibit: Press release dated August 13, 2026 (Exhibit 99.1).
• Authorized signature: /s/ Matthew Angel, Chief Executive Officer.

Why It Matters

• The filing notifies investors that Tempest has released its latest quarterly results and operational updates; the 8-K itself furnishes the press release rather than embedding financial tables in the filing. Retail investors should review Exhibit 99.1 (the press release) for the actual earnings figures, revenue, cash position, guidance (if any), and business or clinical highlights that could affect the company’s outlook and share price.